

University of Groningen

Screening for lung cancer by imaging

Oudkerk, M.; Heuvelmans, M. A.

Published in:
Jbr-Btr

DOI:
[10.5334/jbr-btr.240](https://doi.org/10.5334/jbr-btr.240)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2013

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Oudkerk, M., & Heuvelmans, M. A. (2013). Screening for lung cancer by imaging: The NELSON study. *Jbr-Btr*, 96(3), 163-166. <https://doi.org/10.5334/jbr-btr.240>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

SCREENING FOR LUNG CANCER BY IMAGING: THE NELSON STUDY*

M. Oudkerk, M.A. Heuvelmans¹

The NELSON trial is the first randomised lung cancer screening trial in which pulmonary nodule management is based on volumetry. This led to considerably less false-positive referrals compared to other lung cancer screening trials, with very high negative predictive values found in the first and second screening rounds. Mortality results are still pending, but the knowledge already gained in the NELSON trial and its side-studies provide valuable information in the field of screening for lung cancer.

Key-word: Lung neoplasms, diagnosis.

Lung cancer is a major health problem with no improvement in survival over the last decades. At time of diagnosis, lung cancer is often already in advanced stage, with 5-year survival of no more than 15% (1). Currently, several lung cancer screening trials investigating whether early detection of lung cancer in high-risk individuals will eventually reduce lung cancer mortality are ongoing (2-7). To date, the National Lung Screening Trial (NLST) is the only randomized controlled trial in which a significant lung cancer mortality reduction was found (2).

The Dutch-Belgian lung cancer screening trial (Dutch acronym: NELSON study) was launched in September 2003. The NELSON study is an ongoing multicentre randomized controlled multi-detector low-dose computed tomography lung cancer screening trial. The primary object is to investigate whether chest CT screening in year 1, 2, 4 and 6.5 will decrease lung cancer mortality by at least 25% in high-risk (ex-)smokers between 50 and 75 years of age compared to a control group receiving no screening. Secondary end points of the study include estimation of the cost-effectiveness of the screening programme, assessment of the optimal screening interval (1, 2 or 2.5 years), and assessment of the impact on quality of life. In addition, multiple side studies are ongoing.

One of the major challenges in lung cancer screening is the high false-positive rate, causing patient anxiety, cost and morbidity associated with unnecessary diagnostic procedures for benign nodules. The NELSON trial is the first large lung cancer screening trial in which the nodule management protocol is based on nodule volume, instead of nodule diameter, and nodule growth, in terms of volume doubling time (VDT) of existing nodules. The final

results will indicate whether a volumetry- and VDT based CT protocol is more efficient in terms of detection rate, morbidity, mortality, recall rate, and cost-effectiveness, compared to other approaches.

Methods

Participants

The NELSON multi-centre trial was approved by the Dutch Minister of Health and the ethics board at each participating centre. All participants provided written informed consent. Participants were recruited based on a questionnaire about health, smoking, cancer history, and other lifestyle and health factors. Included were current or former heavy smokers, with a history of > 15 cigarettes daily for > 25 years or > 10 cigarettes daily for > 30 years and between 50-75 years of age. Exclusion criteria were a moderate or bad self reported health, inability to climb two flights of stairs, body weight ≥ 140 kg, lung cancer less than 5 years ago or still under treatment, current or past renal cancer, melanoma or breast cancer, and chest CT less than 1 year ago (8). In total, 15,822 subjects were included. 7,557 were categorized in the screen group, receiving low-dose chest CTs. Participants in the control group received no screening.

Participants in the screen group underwent CT, and depending on the screening round, pulmonary function testing and blood sampling on the same day. After each CT examination, participants completed a quality of life questionnaire.

Data acquisition

The participants randomized to the screen group were invited to one of the four screening sites (University Hospital Groningen, University

Hospital Utrecht and Kennemer Gasthuis Haarlem in the Netherlands and University Hospital Gasthuisberg Leuven in Belgium). All low-dose chest CT scans were performed by using 16-detector helical CT scanners Sensation-16, Siemens Medical Systems or, at the screening site in Utrecht, Mx8000 IDT or Brilliance 16P, Philips Medical Systems). Scanning of the entire chest was performed in a caudo-cranial direction, without the use of contrast agents. Depending on body weight (< 50 kg, 50-80 kg, and > 80 kg), the kVp settings were 80-90, 120 and 140 kVp respectively. This corresponds to an effective radiation dose < 1.6 mSv. Data sets of the lung were reconstructed at 1.0-mm slice thickness, with 0.7-mm reconstruction increment. Scans were performed in inspiration after appropriate instruction of the participants, to minimize breathing artefacts.

Data acquisition and scanning conditions were standard across screening centres and equal for baseline and repeat screening (9).

Volumetric measurements and image reading

Digital workstations (Leonardo, Siemens Medical Solutions) were used for nodule volumetric analysis. This system detected automatically whether a nodule, marked by a radiologist, was new or had been present previously. After a nodule was marked, a program for semi-automated volume measurements (LungCare, version Somaris/5 VB 10A-W, Siemens Medical Solutions) automatically defined the volume of interest around the nodule. An observer could manually modify the segmentation by increasing or decreasing the volume, if necessary (9).

Data generated by the LungCare software were uploaded into the NELSON Management System, which automatically detected whether a nodule was new or present on previous scans. The percentage volume change and VDT of previously detected nodules were calculated

*Meeting "Lung Cancer Imaging in 2012: Updates and innovations", Tervuren, 10.11.2012.
1. University of Groningen, University Medical Center Groningen, Center for Medical Imaging - North East Netherlands, Department of Radiology, Groningen, the Netherlands.

automatically by the system. For each evaluable nodule, the surface characteristics, location, distance to the pleura, and aspect of the nodule (i.e. solid, nonsolid or partial solid) were entered in the NELSON Management System by a radiologist.

All CT images were independently read by first and second readers (double reading) as part of the NELSON protocol (9). The first reading was performed by a reader with experience in reading chest CTs varying from none to more than 20 years; the second reading was performed by two readers, each with 6 years of experience. The second readers were unaware of the conclusions of the first readers. In case of discrepancy, the final decision was made by a third reader (10).

Screening strategy

At baseline, a test was considered positive if any non-calcified nodule was larger than 500 mm³ (> 9.8-mm diameter). The result was indeterminate if the volume of the largest solid nodule or the solid component of a partially-solid nodule was 50-500 mm³ (4.6-9.8-mm diameter). In case of smaller nodules, the screening was negative (9).

Indeterminate nodules underwent a 3-month follow-up CT to assess for growth. Growth was defined as volume increase of at least 25%. For growing nodules, the final result was based on their VDT. If a growing lesion had a VDT < 400 days, the final result was positive. Otherwise the baseline result was negative and the participant was invited for the regular second-round examination in year 2.

At second-round screening, there were two possibilities: either a nodule was new, and the result was based on nodule size, or a nodule was pre-existing. New indeterminate nodules underwent a 6-week follow-up CT. For pre-existing nodules, the second round result was based on their VDT immediately. If both new and existing nodules were present, the nodule with the largest volume or fastest growth determined the result. Again, a VDT < 400 days resulted in a positive screen result. A nodule with VDT > 600 was classified as negative. A VDT of 400-600 days comprised an indeterminate result; then a follow-up CT was made 1 year later. Then, if the VDT was less than 400 days, the final result was positive (Fig. 1), otherwise negative. All participants with a negative second-round result were invited to undergo

the third round examination 2 years after the second round (9).

The protocols of the third and fourth-round examinations were comparable to the protocol of the second-round, except for the fact that the fourth-round examination was planned 2.5 years after the third-round examination. The screening program ended after a positive or negative fourth round result, or, in case of an indeterminate fourth-round result, after a positive or negative follow-up CT (Fig. 2).

Test positives were referred to a pulmonologist for workup. Workup, staging, and treatment were standardized to (inter-) national guidelines (9, 11). Nodules were classified as benign or malignant based on histological examination. Also, nodules could be classified benign based on stable or decreasing size two years after first detection (12, 13). If lung cancer was diagnosed, the participant was treated and left the screening trial; otherwise the regular next-round CT was scheduled.

Results

NELSON screen results

The results of the first and second screening round were published in




Fig. 1. — Growing malignant lesion in a 65-year-old man. Axial computed tomography (CT) scan (A) shows a nodule (arrow) with a volume of 259 mm³ in the left lower lobe. Three months later (B), the nodule volume increased to 270 mm³ (volume-doubling time [VDT] = 1468 days). One year after baseline CT (C), the nodule volume was 425 mm³ (VDT = 528 days). 28 months after baseline CT (D), the nodule volume was 1132 mm³. The VDT at that time was 289 days. Lobectomy revealed a stage IA adenocarcinoma. M.a.b. = months after baseline.




Fig. 2. — Screening programme

the *New England Journal of Medicine* in 2009 (7). In the baseline round, 1.6% of the subjects in the screen group had a nodule with volume $> 500\text{mm}^3$. 19.2% had at least one indeterminate nodule, for which a three-month follow-up CT was performed. In this follow-up CT, growth was demonstrated in only 5.3% of participants with indeterminate nodules. In total, 196/7,557 participants tested positive (2.6%). In 70/196 participants, malignancy was confirmed; the lung cancer detection rate was 0.9%. Sensitivity of the baseline round screening was 94.6%, the negative predictive value was 99.7%. Only three interval cancers were detected between the first and second screening round.

In the second screening round, a total of 7,289 participants underwent screening. The screen result was negative in 92.2% of the participants, indeterminate in 6.6% and positive in 1.2%. After follow-up examinations for indeterminate tested nodules, a total of 128/7,289 participants (1.8%) tested positive. Malignancy was confirmed in 54/118 (45.8%) participants referred for work-up. The lung cancer detection rate was 0.8%. Sensitivity of the second round screening was 96.4%, the negative predictive value was 99.9%.

NELSON vs NLST

Recently, the American National Lung Cancer Screening trial published a 20% lung cancer mortality reduction in their study group which received 3 annual rounds of low-

dose CT screening. The control group received 3 annual rounds of chest X-ray screening (2).

In the NLST screening rounds, the rate of positive tests, defined as greatest nodule diameter of 4 mm or larger, was 24%. No less than 96.4% comprised false positive results. Volume-based nodule management has been suggested to be more accurate than diameter measurements (14, 15), potentially leading to lower false-positive rates. Therefore, the NELSON trial was the first lung cancer screening trial which based screening interpretation on nodule volumetry and growth in terms of volume doubling time instead of diameters. This strategy yielded a rather low rate of positive screening tests (2.6% in the baseline screening; 1.8% in the second-round screening), while the number of missed lung cancers was low.

Additional results of the NELSON study

Valuable knowledge about interobserver variability and the optimal image reading protocol of semi-automated volume measurements was obtained in the NELSON trial. Gietema et al. found that interobserver correlation was very high ($r = 0.99$) in small-to-intermediate size ($15\text{--}500\text{mm}^3$) lung nodules (10). It was also found that variability on volume measurements is related to nodule size, morphology and location (16). In a further study (17), a difference in repeatability among three

reconstruction settings was found. It was shown that volume measurement of pulmonary nodules obtained at 1 mm section thickness combined with a soft kernel was most repeatable. Therefore it was concluded that in case of serial CT studies, consistent reconstruction parameters are essential. Furthermore, compared to single reading, no statistically significant benefit for consensus double reading at baseline screening for lung cancer with the use of a nodule management strategy based solely on semi-automated volumetry was found (18). Therefore, in the fourth screening round image reading was performed by only one reader.

At last, the performance of computer aided detection (CAD) was compared to double reading. The false-positive rate was 3.7 per CT for CAD and 0.5 per CT for readers. Excluding small nodules ($< 50\text{mm}^3$), the false-positive rate for CAD decreased to 1.9. The sensitivity of nodule detection by readers for nodules with need of further evaluation could have increased by 18.6% (from 78.1% to 96.7%) if CAD had also been used. However, only one lung cancer missed by readers was detected by CAD (19).

Three studies focussed on the work-up of pulmonary nodules. In the first (20), it was shown that conventional white-light bronchoscopy should not be routinely recommended for patients with a positive test result in a lung cancer screening trial. The overall sensitivity was 13.5% and the negative predictive value was 47.6%. In the second study (21), the role of a preoperative positron emission tomography after a conclusive or inconclusive nonsurgical workup was evaluated. It was concluded that a preoperative PET scan in participants with an inconclusive nonsurgical workup is not recommended because of the very low negative predictive value. The third study (22) investigated the complication rate in participants of the screen arm of the NELSON lung cancer screening trial who underwent surgical resection. They found that mortality rates after surgical procedures are lower in the NELSON lung cancer screening trial than those in the non-screening series. The rate of complications is within the same range as in the non-screening series.

A number of studies focussed on the characteristics of lung nodules associated with cancer risk. In solid nodules larger than 50mm^3 , especially size, and to a lesser extent irregular shape and margin, were found to increase the likelihood of malignancy (13). Although baseline lung

nodule CT density was not predictive of malignancy, an increase in CT density on follow-up CTs in intermediate-sized nodules suggested lung cancer (23).

Cancers in intermediate-sized (50-500 mm³) fast-growing solid nodules, diagnosed at 3-month or 1-year follow-up CT after baseline, were found to be non-spherical and purely intraparenchymal, without attachment to the pleura, vessels or fissures (24). Perifissural nodules, accounting for about 20% of all lung nodules found in lung cancer screening, can show growth rates in the range of malignant nodules. However, none of the perifissural nodules turned out to be malignant after 5.5 years of follow-up. Therefore, recognition of these nodules can reduce unnecessary workup (25).

Conclusion

The first results of the NELSON study show the value of 3D-based lung nodule management for CT lung cancer screening, with very high negative predictive values found in the first and second screening round. Follow-up of the NELSON study population is ongoing and the mortality results are pending, but the unique methodological features of this randomized trial have already yielded important insights that complement the information gained from NLST.

References

- Janssen-Heijnen M.L., Coebergh J.W.: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. *Lung Cancer*, 2001, 31: 123-137.
- National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*, 2011, 4, 365: 395-409.
- Infante M., Lutman F.R., Cavuto S., Brambilla G., Chiesa G., Passera E., et al.: Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. *Lung Cancer*, 2008, 59: 355-363.
- Lopes Pegna A., Picozzi G., Mascalchi M., Maria Carozzi F., Carozzi L., Comin C., et al.: Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. *Lung Cancer*, 2009, 64: 34-40.
- Blanchon T., Brechot J.M., Grenier P.A., Ferretti G.R., Lemarie E., Milleron B., et al.: Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). *Lung Cancer*, 2007, 58: 50-58.
- Gohagan J.K., Marcus P.M., Fagerstrom R.M., Pinsky P.F., Kramer B.S., Prorok P.C., et al.: Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. *Lung Cancer*, 2005, 47: 9-15.
- van Klaveren R.J., Oudkerk M., Prokop M., Scholten E.T., Nackaerts K., Vernhout R., et al.: Management of lung nodules detected by volume CT scanning. *N Engl J Med*, 2009, 361: 2221-2229.
- van Iersel C.A., de Koning H.J., Draisma G., Mali W.P., Scholten E.T., Nackaerts K., et al.: Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). *Int J Cancer*, 2007, 120: 868-874.
- Xu D.M., Gietema H., de Koning H., Vernhout R., Nackaerts K., Prokop M., et al.: Nodule management protocol of the NELSON randomised lung cancer screening trial. *Lung Cancer*, 2006, 54: 177-184.
- Gietema H.A., Wang Y., Xu D., van Klaveren R.J., de Koning H., Scholten E., et al.: Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. *Radiology*, 2006, 241: 251-257.
- CBO. Guideline - non-small cell lung cancer: staging and treatment. Alphen aan de Rijn, The Netherlands: Van Zuiden Communications BV, 2004.
- MacMahon H., Austin J.H., Gamsu G., Herold C.J., Jett J.R., Naidich D.P., et al.: Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology*, 2005, 237: 395-400.
- Xu D.M., van Klaveren R.J., de Bock G.H., Leusveld A., Zhao Y., Wang Y., et al.: Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. *Eur J Radiol*, 2008, 68: 347-352.
- Yankelevitz D.F., Reeves A.P., Kostis W.J., Zhao B., Henschke C.I.: Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. *Radiology*, 2000, 217: 251-256.
- Revel M.P., Bissery A., Bienvenu M., Aycard L., Lefort C., Frija G.: Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? *Radiology*, 2004, 231: 453-458.
- Wang Y., van Klaveren R.J., van der Zaag-Loonen H.J., de Bock G.H., Gietema H.A., Xu D.M., et al.: Effect of nodule characteristics on variability of semiautomated volume measurements in pulmonary nodules detected in a lung cancer screening program. *Radiology*, 2008, 248: 625-631.
- Wang Y., de Bock G.H., van Klaveren R.J., van Ooyen P., Tukker W., Zhao Y., et al.: Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability. *Eur Radiol*, 2010, 20: 1180-1187.
- Wang Y., van Klaveren R.J., de Bock G.H., Zhao Y., Vernhout R., Leusveld A., et al.: No benefit for consensus double reading at baseline screening for lung cancer with the use of semiautomated volumetry software. *Radiology*, 2012, 262: 320-326.
- Zhao Y., de Bock G.H., Vliegenthart R., van Klaveren R.J., Wang Y., Bogoni L., et al.: Performance of computer-aided detection of pulmonary nodules in low-dose CT: comparison with double reading by nodule volume. *Eur Radiol*, 2012, 22: 2076-2084.
- van 't Westeinde S.C., Horeweg N., Vernhout R.M., Groen H.J., Lammers J.W., Weenink C., et al.: The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules. *Chest*, 2012, 142: 377-384.
- Van't Westeinde S.C., de Koning H.J., Thunnissen F.B., Oudkerk M., Groen H.J., Lammers J.W., et al.: The Role of the (18)F-Fluorodeoxyglucose-Positron Emission Tomography Scan in the Netherlands Leuven Longkanker Screenings Onderzoek Lung Cancer Screening Trial. *J Thorac Oncol*, 2011, 6: 1704-1712.
- Van't Westeinde S.C., Horeweg N., De Leyn P., Groen H.J., Lammers J.W., Weenink C., et al.: Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trial. *Eur J Cardiothorac Surg*, 2012, 42: 420-429.
- Xu D.M., van Klaveren R.J., de Bock G.H., Leusveld A.L., Dorrius M.D., Zhao Y., et al.: Role of baseline nodule density and changes in density and nodule features in the discrimination between benign and malignant solid indeterminate pulmonary nodules. *Eur J Radiol*, 2009, 70: 492-498.
- Xu D.M., van der Zaag-Loonen H.J., Oudkerk M., Wang Y., Vliegenthart R., Scholten E.T., et al.: Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. *Radiology*, 2009, 250: 264-272.
- de Hoop B., van Ginneken B., Gietema H., Prokop M.: Pulmonary Perifissural Nodules on CT Scans: Rapid Growth Is Not a Predictor of Malignancy. *Radiology*, 2012, 265: 611-616.